Barriers to the acceptance of quality antimalarial medicines for children

The Medicines for Malaria Venture (MMV), has released a new independent study in six francophone countries in Central and West Africa. The study focuses on assessing critical barriers to the acceptance and uptake of quality antimalarial medicines for children.


Among key findings are: Drug supply financing and adequate supply chain monitoring represent a significant barrier; Lack of demand by health-care professionals – and willingness to change prescribing patterns – remains a barrier to acceptance.


The study draws on a WHO-endorsed framework for evaluating barriers to access to essential medicines. It suggests interventions that could enhance acceptance and uptake of WHO-recommended medicines for children. The findings and recommendations expressed in this study are those of the author, and do not necessarily reflect the views of MMV.


MMV commissioned this independent study by consultant Dr. Florence Camus-Bablon.


Source: The Medicines for Malaria Venture (MMV)


Go back